Research programme: tryptase inhibitors - Protherics

Drug Profile

Research programme: tryptase inhibitors - Protherics

Alternative Names: Tryptase inhibitors research programme - Protherics

Latest Information Update: 16 Jul 2002

Price : $50

At a glance

  • Originator Protherics
  • Class
  • Mechanism of Action Tryptase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • Discontinued Asthma

Most Recent Events

  • 16 Jul 2002 Discontinued - Preclinical for Asthma in United Kingdom (unspecified route)
  • 10 Mar 2000 Protherics is seeking a development partner for its tryptase inhibitors (
  • 21 Oct 1999 Proteus International has merged with Therapeutic Antibodies to form Protherics
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top